Calcium Dobesilate Monohydrate 0.5 % w/w + Lignocaine HCI. 3.0% w/w Hydrocortisone Acetate 0.25%w/w + Zinc Oxide 5.0%w/w + Chlorocresol 0.1%w/w

Calcium Dobesilate Monohydrate 0.5 % w/w + Lignocaine HCI. 3.0% w/w Hydrocortisone Acetate 0.25%w/w + Zinc Oxide 5.0%w/w + Chlorocresol 0.1%w/w is a topical formulation formulated with Calcium Dobesilate Monohydrate 0.5 % w/w + Lignocaine HCI. 3.0% w/w Hydrocortisone Acetate 0.25%w/w + Zinc Oxide 5.0%w/w + Chlorocresol 0.1%w/w. The listed active ingredient profile is Calcium Dobesilate Monohydrate % w/w; Lignocaine HCI. % w/w Hydrocortisone Acetate w/w; Zinc Oxide w/w; Chlorocresol w/w, placing the product in the topical dermatology category. The formulation is a topical dermatology product whose exact indication should follow the approved product label. The dosage form is intended for topical/local application; the exact application site and frequency must follow the approved product instructions. For website cataloguing, the composition, strength, dosage form and formulation characteristics should be displayed prominently and consistently. The product description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and professional judgement. Prescription status, warnings, interactions, adverse effects and dosing or application instructions must be checked against the current approved product label. Manufacturer, licence, storage, shelf-life, reconstitution where applicable, and market-specific regulatory details should be added only from verified product documentation.